Butaprost (1-4 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment attenuates the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery, as illustrated by a reduction in the gene and protein expression of α-smooth muscle actin, fibronectin and collagen 1A1.
Animal Model: |
Male C57BL/6 mice (8 weeks of age; 21 g) bearing unilateral ureteral obstruction surgery |
Dosage: |
1 mg/kg, 2 mg/kg, 4 mg/kg |
Administration: |
Intraperitoneal injection; twice daily; for 7 days |
Result: |
Attenuated the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery. |